US Patent 11,986,481 Scope and Claims Analysis: Method-of-Treatment and Composition Claims for a Defined Fatty Liver Drug Candidate
US Patent 11,986,481 claims a tightly defined, small-molecule active ingredient (by full chemical name) and limits protection to treating fatty liver disease, with preferred coverage for nonalcoholic steatohepatitis (NASH), using specified daily dosing ranges (20 mg to 100 mg per day) and oral tablet administration, including purity thresholds and single-dose regimens. The claim set is method-of-use plus method-of-treatment via a pharmaceutical composition, with no independent claim apparent for manufacturing, device, or diagnostic use.
Core protected subject matter
- Treatment indication: “fatty liver disease,” with explicit dependent fallback to nonalcoholic steatohepatitis.
- Active ingredient specificity: claims recite 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (or a pharmaceutically acceptable salt).
- Dose and regimen limits: 20 mg to 100 mg per day, with dependent claim to 100 mg/day and single daily dose.
- Administration route and dosage form: oral; dependent claim to tablet.
- Additional constraints: purity of ≥95% (and dependent ≥98%).
- Salt coverage: explicitly includes “pharmaceutically acceptable salt,” but with no additional salt identity recited.
What is the invention protected by US Patent 11,986,481—active ingredient, dose, and indication?
Claim 1 (method for treating fatty liver disease) is the foundation. It is structured as:
- A patient treatment method
- The specific compound (or salt)
- A dosing range (20–100 mg/day)
What disease scope do the claims cover?
- Claim 1: “fatty liver disease” (broad within that phrase).
- Claim 2 (dependent): “fatty liver disease is nonalcoholic steatohepatitis.”
Implication for scope: protection is available for fatty liver disease generally, but NASH is the explicit, patent-backed subpopulation. If later regulatory labeling is limited to NASH (or NASH with fibrosis stages), enforcement alignment is strongest for claim 2.
What dosing scope exists?
- Claim 1: about 20 mg to about 100 mg per day
- Claim 3: about 100 mg per day
- Claim 6: “daily as a single dose” (regimen constraint)
Implication for scope: the dosing range is broad enough to cover multiple dose-finding outcomes within 20–100 mg/day. However, claims do not cover doses below 20 mg/day or above 100 mg/day.
What route and dosage form scope exists?
- Claim 4: administered orally
- Claim 5: tablet comprises the compound (or salt) and is administered orally.
Implication for scope: if competitors launch with a non-oral route (e.g., injectable or infusion), they may fall outside claim 4/5, while still potentially reading on claim 1 (depending on how “administering” is interpreted). But because claim 4 and 5 narrow route/dosage form, enforceability outside oral/tablet becomes a key design-around dimension.
How broadly do the claims cover salts, purity, and pharmaceutical form factors?
Salt coverage: “pharmaceutically acceptable salt”
Claims 1 and 10 (and dependents) cover:
- the free base compound
- “a pharmaceutically acceptable salt thereof”
There is no claim language requiring a specific salt identity, counterion, or salt form.
Enforcement posture: salts that qualify as “pharmaceutically acceptable” remain in-scope. If a challenger uses a non-salt form (e.g., free acid/base versus salt), the claim explicitly includes the non-salt compound anyway, so the salt route mainly affects formulation strategy rather than basic infringement avoidance.
Purity thresholds: 95% and 98%
- Claim 7: compound has purity of 95% or greater
- Claim 8: compound has purity of 98% or greater
Claim mechanics impact: these dependents can tighten infringement to manufacturing/material specifications. If an accused product sources material with lower stated purity or uses different analytical definitions (or provides CoA values below threshold), the purity dependents can be harder to prove, though Claim 1 and 10 are not purity-limited.
Pharmaceutical composition claim scope: excipient/carrier inclusion
Claim 10 covers a method via administration of:
- a “pharmaceutical composition comprising” the compound (or salt) plus
- “at least one pharmaceutically acceptable excipient or carrier”
- suitable for dosing from 20–100 mg/day
This claim is broad in that it does not require a specific excipient identity, coating, binder, disintegrant, or tablet composition beyond suitability.
Route and tablet constraints reappear in composition form
- Claim 13: composition administered orally
- Claim 14: composition is a tablet
- Claim 15: single dose daily
Which dependent claims narrow the protected activity the most, and how can that shape design-arounds?
Highest “design-around sensitivity” dependents
- Oral route limitation (Claim 4 / 13)
- If a product is not orally administered, it may avoid those narrower claims.
- Tablet limitation (Claim 5 / 14)
- If a product is oral but not a tablet (capsule, film, solution, granules, sachet), tablet-specific claim 5/14 may not read.
- Single daily dose limitation (Claim 6 / 15)
- A regimen split-dose (e.g., twice daily) could avoid those dependents.
- Purity thresholds (Claims 7–8 / 16–17)
- If an accused manufacturer disputes purity or uses different specification levels, the dependent claims become litigation targets on evidentiary footing.
Lower sensitivity dependents
- NASH-specific dependent (Claim 2 / 11) narrows disease context only, not the drug.
Mainstay enforceability remains Claims 1 and 10
Because Claim 1 and Claim 10 do not require tablet form, single-dose, or purity thresholds, they are the most durable coverage. Design-around efforts tend to target route, dosage form, dosing amount, or disease definition in labeling/clinical protocol to reduce overlap with narrowed claims.
How does US 11,986,481 compare between the method-of-use claims (Claims 1–9) and the composition-based method claims (Claims 10–18)?
Claim set architecture
- Claims 1–9: method for treating fatty liver disease by administering the compound at 20–100 mg/day, with dependents adding NASH, 100 mg/day, oral/tablet, single dose, and purity.
- Claims 10–18: method for treating fatty liver disease via administering a pharmaceutical composition containing the compound plus excipient/carrier, with the same parallel narrowing elements (NASH, 100 mg/day, oral/tablet, single dose, purity).
Overlap and redundancy
Claims 1 and 10 both cover the same therapeutic use and dosing concept, with Claim 10 explicitly tying infringement to a composition comprising the drug plus excipients.
Practical effect: If a competitor’s infringement theory focuses on composition product form, Claim 10 supplies an additional hook. If a competitor disputes the “composition” characterization, Claim 1 still targets administration of the active ingredient with dosing limits.
What is the likely claim construction pinch-points for infringement analysis?
1) “about 20 mg to about 100 mg per day”
This introduces a range with “about,” which generally expands tolerance around the recited numerical values. Still, a dosing regimen outside the range (such as 10 mg/day or 150 mg/day) is a clearer non-infringement path.
2) “administering” and patient population
Method-of-use claims require performance in a subject. Enforcement can hinge on:
- clinical protocol dose actually administered
- labeling and physician use (for NASH/fatty liver disease)
- evidence of regimen (single daily dose vs split)
3) “fatty liver disease” breadth
If “fatty liver disease” is treated as encompassing NAFLD and NASH, Claim 1 can be broad enough to cover NAFLD as well, unless construed narrowly. Claim 2 makes NASH explicit, reducing ambiguity for that sub-indication.
What does the claim set suggest about the underlying compound’s IP strategy?
The patent appears to be a clinical-use/dosing and formulation-facing continuation-style play rather than a core chemical-structure patent (because:
- it recites the compound in full,
- it is limited to a specific dose range and administration format,
- it includes excipient/tablet features and purity requirements.
IP strategy inference (strict to claim text):
- Prior art blocking likely addressed the compound structure elsewhere.
- This patent locks in the practical dosing and use parameters for fatty liver disease.
- The existence of tablet and single-dose dependents suggests product commercialization targets oral solid dosage and once-daily convenience.
How does the claim scope map to FDA development and labeling risk?
The claims are written around a dosing range and fatty liver indications. If the eventual FDA label is limited to NASH (common for nonalcoholic steatohepatitis programs) and uses once-daily oral dosing in the 20–100 mg/day band, the patent alignment is strong.
Label/design alignment matrix (derived from claim text)
- NASH in label: supports Claims 2/11.
- Oral dosing in label: supports Claims 4/13.
- Tablet in label: supports Claims 5/14.
- Once-daily dosing in label: supports Claims 6/15.
- Drug substance purity control in manufacturing specs: supports Claims 7–8/16–17.
If a generic or competitor seeks to launch with a different administration form or regimen, design-around depends on whether the core active ingredient remains the same and whether they can stay outside the narrower dependents. Even then, Claims 1 and 10 remain possible.
What generic entry risks exist for products that contain the same active ingredient?
Risk drivers
- If a generic uses the same compound (or pharmaceutically acceptable salt) and is dosed within 20–100 mg/day, Claims 1/10 remain at risk.
- If generic product is oral/tablet and dosed once daily, dependents add incremental enforceability.
Risk reduction levers (based on claim language)
- Dose outside 20–100 mg/day (hard clinically if efficacy requires within band).
- Non-oral administration (route design-around).
- Avoid tablet form (but not necessarily avoid Claim 1/10 since those do not require tablet).
- Split dosing to avoid “single dose” dependents.
- Manufacture drug with purity below 95% or challenge purity proof for dependents (but does not avoid Claims 1/10).
Patent landscape summary for US 11,986,481: what else must exist in the estate to matter?
US 11,986,481 is a method-of-treatment patent that depends on the existence of the drug substance already being in commerce or clinical development. For business decisions, the estate typically includes:
- earlier compound patents (structure, stereochemistry, polymorphs, salts, intermediates) that provide baseline chemical exclusivity
- later use, dosing, and formulation patents like this one that extend enforceable time and complicate generic entry
However, only the claim text was provided here. No bibliographic data, prosecution history, other asserted patents, or Orange Book listings were included, so the broader estate cannot be enumerated without risking inaccuracies.
Key Takeaways
- US 11,986,481 is anchored by two core claims: administration of a defined active ingredient (or pharmaceutically acceptable salt) to treat fatty liver disease at 20–100 mg/day (Claims 1 and 10).
- Dependents lock in commercially relevant parameters: NASH, 100 mg/day, oral and specifically tablet, once-daily single dose, and ≥95%/≥98% purity of the active ingredient.
- The most durable infringement hooks are Claims 1 and 10 because they avoid tablet, purity, and single-dose limitations.
- The highest design-around leverage sits in avoiding overlap with dependent claims: non-oral route, non-tablet oral forms, split dosing, and creating evidentiary or specification disputes around purity.
FAQs
1) Does US 11,986,481 require the patient to have NASH specifically?
No. The independent claims cover “fatty liver disease” generally; NASH is explicitly covered only in dependent claims.
2) If a product doses above 100 mg/day, does it avoid the patent?
The independent claims are limited to “about 20 mg to about 100 mg per day,” so dosing meaningfully outside that range is not within the claim text.
3) Can a once-daily capsule avoid the tablet-dependent claims?
Tablet-dependent claims require a tablet. A capsule may avoid those dependents, but Claims 1 and 10 do not require tablet form.
4) Is the method limited to single daily dosing?
Single daily dose appears only in dependent claims (Claims 6 and 15). The independent claims do not include the single-dose limitation.
5) Do purity thresholds matter for infringement?
Purity thresholds are only in dependent claims (Claims 7–8 and 16–17). They add constraints, but do not limit the independent claims in the provided claim set.
References
- United States Patent 11,986,481 (claim text provided by user).
